stockportfolio.pro
Zevra Therapeutics, Inc. (ZVRA)
Healthcare · Biotechnology · NasdaqGS
Zevra Therapeutics, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $12.84M | $13.29M | $28.65M | $10.16M | $27.46M | $23.61M | $106.47M |
| Gross profit | — | — | — | $2.84M | — | $26.59M | $9.94M | $25.29M | $16.20M | $89.99M |
| Net income | $-16.52M | $-43.39M | $-56.47M | $-24.52M | $-12.76M | $-8.55M | $-26.77M | $-46.05M | $-105.51M | $83.23M |
| Net margin | — | — | — | -191.0% | -96.0% | -29.9% | -263.5% | -167.7% | -446.9% | 78.2% |
Source: Zevra Therapeutics, Inc. SEC filings (10-K). 13 years of history available in the interactive view.
Explore 13 years of Zevra Therapeutics, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track ZVRA in your portfolio →
Zevra Therapeutics, Inc. financial history by metric
About Zevra Therapeutics, Inc.
Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 3 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 3 clinical trial to treat narcolepsy. The company is developing Celiprolol, an investigational product candidate that is under Phase 3 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit and hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and MIPLYFFA for the treatment of niemann-pick disease type C, an ultra-rare neurodegenerative disease. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. The company was incorporated in 2006 and is headquartered in Boston, Massachusetts.
Zevra Therapeutics, Inc. — frequently asked questions
What is Zevra Therapeutics, Inc.'s revenue?
Zevra Therapeutics, Inc. (ZVRA) reported revenue of $106.47M for fiscal year 2025, up 350.9% from the prior year, according to its SEC filings.
Is Zevra Therapeutics, Inc. profitable?
Yes. ZVRA earned net income of $83.23M in fiscal 2025, a net margin of 78.2%.
What is ZVRA's P/E ratio?
Zevra Therapeutics, Inc. trades at a price-to-earnings ratio of about 6.4 based on the latest data in our nightly-refreshed cache.
How fast is Zevra Therapeutics, Inc. growing?
ZVRA's revenue grew at roughly 51.6% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Zevra Therapeutics, Inc. have?
As of fiscal year 2025, ZVRA carried roughly $61.93M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Zevra Therapeutics, Inc.'s gross margin?
ZVRA's gross margin was 84.5% in fiscal 2025 — gross profit of $89.99M on revenue of $106.47M.
What is Zevra Therapeutics, Inc.'s market cap?
Zevra Therapeutics, Inc. (ZVRA) has a market capitalization of about $766.13M, based on the latest data in our nightly-refreshed cache.
When does Zevra Therapeutics, Inc.'s fiscal year end?
ZVRA's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Zevra Therapeutics, Inc.'s official SEC filings (10-K and 10-Q), covering 13 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.